培维索孟治疗期间的脂肪营养不良：一例病例报告及文献综述 - Suppr

Suppr

超能文献

Lipodystrophy during pegvisomant therapy: a case report and review of the literature.

作者信息

Buyuktas D, Celik O, Kantarci F, Kadioglu P

出版信息

Clinics (Sao Paulo). 2010;65(9):931-3. doi: 10.1590/s1807-59322010000900018.

DOI:10.1590/s1807-59322010000900018

PMID:21049223

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2954746/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed5d/2954746/a3181ce2d930/cln-65-09-931-g001.jpg

相似文献

Lipodystrophy during pegvisomant therapy: a case report and review of the literature.培维索孟治疗期间的脂肪营养不良：一例病例报告及文献综述

Clinics (Sao Paulo). 2010;65(9):931-3. doi: 10.1590/s1807-59322010000900018.

Lipodystrophy in patients with acromegaly receiving pegvisomant.接受培维索孟治疗的肢端肥大症患者的脂肪代谢障碍

J Clin Endocrinol Metab. 2008 Sep;93(9):3515-8. doi: 10.1210/jc.2008-0833. Epub 2008 Jul 8.

Subcutaneous lipoatrophy induced by long-term pegvisomant administration.长期使用培维索孟导致的皮下脂肪萎缩

Clin Endocrinol (Oxf). 2009 Apr;70(4):655-6. doi: 10.1111/j.1365-2265.2008.03400.x. Epub 2008 Sep 2.

Pegvisomant-induced lipohypertrophy: report of a case with histopathology.

Ann Intern Med. 2007 Nov 20;147(10):741-3. doi: 10.7326/0003-4819-147-10-200711200-00019.

Lipohypertrophy in acromegaly induced by the new growth hormone receptor antagonist pegvisomant.新型生长激素受体拮抗剂培维索孟诱导的肢端肥大症中的脂肪增生。

Ann Intern Med. 2006 Aug 15;145(4):310-2. doi: 10.7326/0003-4819-145-4-200608150-00017.

Escape and lipodystrophy in acromegaly during pegvisomant therapy, a retrospective multicentre Spanish study.培维索孟治疗肢端肥大症时的逃逸和脂肪代谢障碍，一项西班牙多中心回顾性研究

Clin Endocrinol (Oxf). 2014 Dec;81(6):883-90. doi: 10.1111/cen.12440. Epub 2014 Mar 19.

Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY.肢端肥大症患者使用培维索孟的长期安全性：ACROSTUDY 中 1288 例患者的综合评估。

J Clin Endocrinol Metab. 2012 May;97(5):1589-97. doi: 10.1210/jc.2011-2508. Epub 2012 Feb 22.

Pegvisomant: a novel pharmacotherapy for the treatment of acromegaly.培维索孟：一种用于治疗肢端肥大症的新型药物疗法。

Expert Opin Biol Ther. 2004 Mar;4(3):421-5. doi: 10.1517/14712598.4.3.421.

Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.使用生长激素受体拮抗剂培维索孟治疗肢端肥大症。

N Engl J Med. 2000 Apr 20;342(16):1171-7. doi: 10.1056/NEJM200004203421604.

The role of pegvisomant in the treatment of acromegaly.培维索孟在肢端肥大症治疗中的作用。

Expert Opin Biol Ther. 2008 May;8(5):691-704. doi: 10.1517/14712598.8.5.691.

引用本文的文献

Medical therapy of acromegaly.肢端肥大症的医学治疗。

Int J Endocrinol. 2012;2012:268957. doi: 10.1155/2012/268957. Epub 2012 Apr 10.

本文引用的文献

Pituitary tumours: acromegaly.垂体肿瘤：肢端肥大症。

Best Pract Res Clin Endocrinol Metab. 2009 Oct;23(5):555-74. doi: 10.1016/j.beem.2009.05.010.

Subcutaneous lipoatrophy induced by long-term pegvisomant administration.长期使用培维索孟导致的皮下脂肪萎缩

Clin Endocrinol (Oxf). 2009 Apr;70(4):655-6. doi: 10.1111/j.1365-2265.2008.03400.x. Epub 2008 Sep 2.

Lipodystrophy in patients with acromegaly receiving pegvisomant.接受培维索孟治疗的肢端肥大症患者的脂肪代谢障碍

J Clin Endocrinol Metab. 2008 Sep;93(9):3515-8. doi: 10.1210/jc.2008-0833. Epub 2008 Jul 8.

Pegvisomant-induced lipohypertrophy: report of a case with histopathology.

Ann Intern Med. 2007 Nov 20;147(10):741-3. doi: 10.7326/0003-4819-147-10-200711200-00019.

Lipohypertrophy in acromegaly induced by the new growth hormone receptor antagonist pegvisomant.新型生长激素受体拮抗剂培维索孟诱导的肢端肥大症中的脂肪增生。

Ann Intern Med. 2006 Aug 15;145(4):310-2. doi: 10.7326/0003-4819-145-4-200608150-00017.

Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly.生长激素受体拮抗剂：肢端肥大症患者的发现、研发及应用

Endocr Rev. 2002 Oct;23(5):623-46. doi: 10.1210/er.2001-0022.

[Localized lipohypertrophy during growth hormone therapy].[生长激素治疗期间的局部脂肪增生]

Ugeskr Laeger. 2002 Apr 1;164(14):1930-2.

Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist.使用生长激素受体拮抗剂培维索孟长期治疗肢端肥大症。

Lancet. 2001 Nov 24;358(9295):1754-9. doi: 10.1016/s0140-6736(01)06844-1.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验